FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3009270960> ?p ?o ?g. }

• W3009270960 abstract "Abstract Background Gemcitabine/erlotinib treatment offers limited benefit in unselected patients with pancreatic ductal adenocarcinoma (PDAC). Development of skin rash has been associated with favorable outcomes in patients treated with gemcitabine/erlotinib. This study aimed to extend knowledge on the effectiveness of gemcitabine/erlotinib in metastatic PDAC in the context of clinical practice and with focus on skin rash. Methods This multicenter, non-interventional study enrolled 376 patients with metastatic PDAC receiving gemcitabine/erlotinib. The primary endpoint was overall survival (OS) in patients with skin rash versus no skin rash. Secondary endpoints included progression-free survival (PFS), treatment satisfaction and safety. All data were analyzed using descriptive statistics. Survival time and time to disease progression were estimated using the Kaplan-Meier method. Effectiveness endpoints were analyzed for subgroups by skin rash grade (no rash, rash grade 1, rash grade ≥ 2), duration of erlotinib treatment (≤8 weeks, > 8 weeks), Eastern Cooperative Oncology Group (ECOG) performance status at baseline (0–1, 2) and age (≤65 years, > 65 years). Results Within the full analysis set (FAS; N = 270), 48 patients (17.8%) developed grade 1 rash, 51 patients (18.9%) grade ≥ 2 rash, while 171 patients (63.3%) did not develop a rash. Median OS of all patients was 9.11 months with an OS of 9.93 months in rash-positive and 8.68 months in rash-negative patients. Median PFS was 5.06 months for rash-positive and 4.11 months for rash-negative patients. PFS was longer in patients with rash grade ≥ 2 and in older patients (> 65 years). Examination using a multivariate Cox proportional model revealed that an age > 65 years was associated with longer OS (hazard ratio 0.640; p = 0.0327) and PFS (hazard ratio 0.642; p = 0.0026). Out of the 338 patients in the SAF, 310 patients (91.7%) experienced at least one AE, and 176 patients (52.1%) experienced skin-related side effects, all of which were CTC grade 1 to 3. Conclusions Comparing rash-positive with rash-negative patients showed no significant difference in survival. While patients with rash grade ≥ 2 and older patients (independent of skin reactions) showed longer PFS, this did not translate into prolonged OS. The study did not reveal new safety signals. Trial registration ClinicalTrials.gov Identifier: NCT01782690 , retrospectively registered on 4 February 2013." @default.
• W3009270960 created "2020-03-13" @default.
• W3009270960 creator A5005128603 @default.
• W3009270960 creator A5010141377 @default.
• W3009270960 creator A5014847815 @default.
• W3009270960 creator A5015177424 @default.
• W3009270960 creator A5017297629 @default.
• W3009270960 creator A5023251571 @default.
• W3009270960 creator A5028938155 @default.
• W3009270960 creator A5035848239 @default.
• W3009270960 creator A5043050716 @default.
• W3009270960 creator A5048446588 @default.
• W3009270960 creator A5053960245 @default.
• W3009270960 date "2020-02-24" @default.
• W3009270960 modified "2023-10-14" @default.
• W3009270960 title "Correlation of skin rash and overall survival in patients with pancreatic cancer treated with gemcitabine and erlotinib – results from a non-interventional multi-center study" @default.
• W3009270960 cites W1931508686 @default.
• W3009270960 cites W1968812902 @default.
• W3009270960 cites W2096385798 @default.
• W3009270960 cites W2102509488 @default.
• W3009270960 cites W2115898240 @default.
• W3009270960 cites W2151253787 @default.
• W3009270960 cites W2158134441 @default.
• W3009270960 cites W2158798157 @default.
• W3009270960 cites W2165480504 @default.
• W3009270960 cites W2187917981 @default.
• W3009270960 cites W2339940212 @default.
• W3009270960 cites W2469831351 @default.
• W3009270960 cites W2593516067 @default.
• W3009270960 cites W2605366445 @default.
• W3009270960 cites W2738938634 @default.
• W3009270960 cites W2790596471 @default.
• W3009270960 cites W4210976084 @default.
• W3009270960 doi "https://doi.org/10.1186/s12885-020-6636-7" @default.
• W3009270960 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7041266" @default.
• W3009270960 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32093649" @default.
• W3009270960 hasPublicationYear "2020" @default.
• W3009270960 type Work @default.
• W3009270960 sameAs 3009270960 @default.
• W3009270960 citedByCount "2" @default.
• W3009270960 countsByYear W30092709602021 @default.
• W3009270960 countsByYear W30092709602023 @default.
• W3009270960 crossrefType "journal-article" @default.
• W3009270960 hasAuthorship W3009270960A5005128603 @default.
• W3009270960 hasAuthorship W3009270960A5010141377 @default.
• W3009270960 hasAuthorship W3009270960A5014847815 @default.
• W3009270960 hasAuthorship W3009270960A5015177424 @default.
• W3009270960 hasAuthorship W3009270960A5017297629 @default.
• W3009270960 hasAuthorship W3009270960A5023251571 @default.
• W3009270960 hasAuthorship W3009270960A5028938155 @default.
• W3009270960 hasAuthorship W3009270960A5035848239 @default.
• W3009270960 hasAuthorship W3009270960A5043050716 @default.
• W3009270960 hasAuthorship W3009270960A5048446588 @default.
• W3009270960 hasAuthorship W3009270960A5053960245 @default.
• W3009270960 hasBestOaLocation W30092709601 @default.
• W3009270960 hasConcept C121608353 @default.
• W3009270960 hasConcept C126322002 @default.
• W3009270960 hasConcept C143998085 @default.
• W3009270960 hasConcept C151730666 @default.
• W3009270960 hasConcept C203092338 @default.
• W3009270960 hasConcept C2778087573 @default.
• W3009270960 hasConcept C2778570526 @default.
• W3009270960 hasConcept C2779343474 @default.
• W3009270960 hasConcept C2779438470 @default.
• W3009270960 hasConcept C2780258809 @default.
• W3009270960 hasConcept C2909325608 @default.
• W3009270960 hasConcept C535046627 @default.
• W3009270960 hasConcept C71924100 @default.
• W3009270960 hasConcept C86803240 @default.
• W3009270960 hasConceptScore W3009270960C121608353 @default.
• W3009270960 hasConceptScore W3009270960C126322002 @default.
• W3009270960 hasConceptScore W3009270960C143998085 @default.
• W3009270960 hasConceptScore W3009270960C151730666 @default.
• W3009270960 hasConceptScore W3009270960C203092338 @default.
• W3009270960 hasConceptScore W3009270960C2778087573 @default.
• W3009270960 hasConceptScore W3009270960C2778570526 @default.
• W3009270960 hasConceptScore W3009270960C2779343474 @default.
• W3009270960 hasConceptScore W3009270960C2779438470 @default.
• W3009270960 hasConceptScore W3009270960C2780258809 @default.
• W3009270960 hasConceptScore W3009270960C2909325608 @default.
• W3009270960 hasConceptScore W3009270960C535046627 @default.
• W3009270960 hasConceptScore W3009270960C71924100 @default.
• W3009270960 hasConceptScore W3009270960C86803240 @default.
• W3009270960 hasIssue "1" @default.
• W3009270960 hasLocation W30092709601 @default.
• W3009270960 hasLocation W30092709602 @default.
• W3009270960 hasLocation W30092709603 @default.
• W3009270960 hasLocation W30092709604 @default.
• W3009270960 hasLocation W30092709605 @default.
• W3009270960 hasLocation W30092709606 @default.
• W3009270960 hasOpenAccess W3009270960 @default.
• W3009270960 hasPrimaryLocation W30092709601 @default.
• W3009270960 hasRelatedWork W1972415660 @default.
• W3009270960 hasRelatedWork W2038257329 @default.
• W3009270960 hasRelatedWork W2065093995 @default.
• W3009270960 hasRelatedWork W2089664277 @default.
• W3009270960 hasRelatedWork W2312414451 @default.
• W3009270960 hasRelatedWork W2590692409 @default.
• W3009270960 hasRelatedWork W2888532212 @default.
• W3009270960 hasRelatedWork W2911867799 @default.

• next